← Catalyst calendarRXRX biotech catalysts & pipeline
RECURSION PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
REC-1245 — Full data
H2 2026
REC-1245 is a potential first-in-class oral molecular glue designed to exploit a synthetic-lethal vulnerability in cancers by degrading RBM39, a splicing factor that regulates genes involved in DNA repair and stress response. The target emerged from Recursion's platform, which found that degrading RBM39 mimics the loss of CDK12, while sparing CDK13-associated liabilities. REC-1245 was identified within 18 months after synthesizing only 204 compounds using Recursion's design platform. Additional Phase 1 monotherapy data are expected in the second half of 2026, and preliminary dose expansion data in endometrial cancer are expected in the second half of 2027. Dose escalation will also continue in other solid tumors.
Source filingREC-4881 — FDA meeting
2H26
• Discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26
Source filingREC-4881 — Regulatory decision
in 2H26
Discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26
Source filingREC-3565 — Interim data
1H27
Early Phase 1 safety and PK monotherapy data expected in 1H27
Source filingREC-4881 — Initial data
H1 2027
We expect to provide additional clinical data in the first half of 2027.
Source filingREC-617 — Interim data
1H27
Early Phase 1 safety and PK combination data expected in 1H27
Source filingREC-1245 — Initial data
H2 2027
REC-1245 is a potential first-in-class oral molecular glue designed to exploit a synthetic-lethal vulnerability in cancers by degrading RBM39, a splicing factor that regulates genes involved in DNA repair and stress response. The target emerged from Recursion's platform, which found that degrading RBM39 mimics the loss of CDK12, while sparing CDK13-associated liabilities. REC-1245 was identified within 18 months after synthesizing only 204 compounds using Recursion's design platform. Additional Phase 1 monotherapy data are expected in the second half of 2026, and preliminary dose expansion data in endometrial cancer are expected in the second half of 2027. Dose escalation will also continue in other solid tumors.
Source filingREC-4539 — Interim data
2H27
Early Phase 1 safety and PK monotherapy data expected in 2H27
Source filingREC-4881 — Conference presentation
Nov 2
Additional REC-4881 Phase 1b/2 data as of September 10, 2026 will be presented at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting on Monday, November 2.
Source filingExplore the free biotech catalyst calendar
